Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Abstract 7555: Selective inhibition of the CoREST complex as a novel therapeutic target of atypical teratoid rhabdoid tumors

Anupa Geethadevi, Marianne Collard, Tyler Findlay, Yiming Deng, Robert Fisher, Nikhil Vaidya, Charles Eberhart, Philip A. Cole, Rhoda Alani, Jeffrey Rubens, Eric Raabe

Cancer Res (2024) 84 (6_Supplement): 7555.

https://doi.org/10.1158/1538-7445.AM2024-7555

Published: 22 March 2024

View article titled, Abstract 7555: Selective inhibition of the CoREST complex as a novel therapeutic target of atypical teratoid rhabdoid tumors

Journal Articles

Abstract 5109: Novel acylfulvene LP184 shows single agent and combinatorial efficacy with PARP inhibitors in atypical teratoid rhabdoid tumors

Abigail Tindall, Hyuk J. Kwon, Istabraq Musa, Tyler Findlay, Su Chan Lee, Charles Eberhart, Eric Raabe

Cancer Res (2024) 84 (6_Supplement): 5109.

https://doi.org/10.1158/1538-7445.AM2024-5109

Published: 22 March 2024

View article titled, Abstract 5109: Novel acylfulvene LP184 shows single agent and combinatorial efficacy with PARP inhibitors in atypical teratoid rhabdoid tumors

Journal Articles

Abstract 6565: Improving survival of atypical teratoid/rhabdoid tumor orthotopic xenografts through the combination of PI3K inhibitor paxalisib and nucleoside analog gemcitabine

Tyler Findlay, Kristen Malebranche, Anupa Geethadevi, Charles Eberhart, Jeffrey Rubens, Eric Raabe

Cancer Res (2024) 84 (6_Supplement): 6565.

https://doi.org/10.1158/1538-7445.AM2024-6565

Published: 22 March 2024

View article titled, Abstract 6565: Improving survival of atypical teratoid/rhabdoid tumor orthotopic xenografts through the combination of PI3K inhibitor paxalisib and nucleoside analog gemcitabine

Journal Articles

Abstract 6498: MEK inhibitor mirdametinib suppresses MAP kinase pathway activity and inhibits tumor growth in atypical teratoid/rhabdoid tumors

Yiming Deng, Kristen Malebranche, Tyler Findlay, Anupa Geethadevi, Charles Eberhart, Jeffrey Rubens, Eric Raabe

Cancer Res (2024) 84 (6_Supplement): 6498.

https://doi.org/10.1158/1538-7445.AM2024-6498

Published: 22 March 2024

View article titled, Abstract 6498: MEK inhibitor mirdametinib suppresses MAP kinase pathway activity and inhibits tumor growth in atypical teratoid/rhabdoid tumors

Journal Articles

Abstract 1141: The CoREST complex as a novel target to disrupt AT/RT’s abnormal epigenetic landscape

Anupa Geethadevi, Marianne Collard, Nikhil Vaidya, Tyler Findlay, Kristen Malebranche, Charles Eberhart, Eric Raabe, Philip Cole, Rhoda Alani, Jeffrey Rubens

Cancer Res (2023) 83 (7_Supplement): 1141.

https://doi.org/10.1158/1538-7445.AM2023-1141

Published: 04 April 2023

View article titled, Abstract 1141: The CoREST complex as a novel target to disrupt AT/RT’s abnormal epigenetic landscape

Journal Articles

Abstract 5509: The PI3K inhibitor Paxalisib combines synergistically with the MEK inhibitor Mirdametinib to target atypical teratoid/rhabdoid tumors

Kristen J. Malebranche, Tyler Findlay, Anupa Geethadevi, Charles Eberhart, Eric Raabe, Jeffrey Rubens

Cancer Res (2023) 83 (7_Supplement): 5509.

https://doi.org/10.1158/1538-7445.AM2023-5509

Published: 04 April 2023

View article titled, Abstract 5509: The PI3K inhibitor Paxalisib combines synergistically with the MEK inhibitor Mirdametinib to target atypical teratoid/rhabdoid tumors

Journal Articles

Abstract 5490: Combination of the PI3k inhibitor Paxalisib with the nucleoside analog Gemcitabine over-activates the integrated stress response and induces atypical teratoid/rhabdoid tumor cell death

Tyler Findlay, Kristen Malebranche, Anupa Geethadevi, Eric Raabe, Charles Eberhart, Jeffrey Rubens

Cancer Res (2023) 83 (7_Supplement): 5490.

https://doi.org/10.1158/1538-7445.AM2023-5490

Published: 04 April 2023

View article titled, Abstract 5490: Combination of the PI3k inhibitor Paxalisib with the nucleoside analog Gemcitabine over-activates the integrated stress response and induces atypical teratoid/rhabdoid tumor cell death

Journal Articles

Abstract 6720: Using proteasome inhibition to hyperactivate the integrated stress response in aggressive pediatric brain tumors

Orlandi Valencia Novak, Tyler Findlay, Jeffrey Rubens, Charles Eberhart, Eric H. Raabe

Cancer Res (2023) 83 (7_Supplement): 6720.

https://doi.org/10.1158/1538-7445.AM2023-6720

Published: 04 April 2023

View article titled, Abstract 6720: Using proteasome inhibition to hyperactivate the integrated stress response in aggressive pediatric brain tumors

Journal Articles

Abstract 4990: Dual inhibitor of ACVR1 and MEK 1/2 E6201 and PI3K/mTOR inhibitor paxalisib synergistically inhibit cell growth in DMG

Hyuk Jean Kwon, Abigail Tindall, Charles Eberhart, Jeffrey Rubens, Eric Raabe

Cancer Res (2023) 83 (7_Supplement): 4990.

https://doi.org/10.1158/1538-7445.AM2023-4990

Published: 04 April 2023

View article titled, Abstract 4990: Dual inhibitor of ACVR1 and MEK 1/2 E6201 and PI3K/mTOR inhibitor paxalisib synergistically inhibit cell growth in DMG

Journal Articles

Abstract 5472: Inhibiting the TET pathway in diffuse midline glioma reduces levels of 5-hydroxymethylcytosine and increases levels of 5-methylcytosine

Akhila Parthasarathy, Antje Arnold, Charles Eberhart, Eric Raabe

Cancer Res (2022) 82 (12_Supplement): 5472.

https://doi.org/10.1158/1538-7445.AM2022-5472

Published: 15 June 2022

View article titled, Abstract 5472: Inhibiting the TET pathway in diffuse midline glioma reduces levels of 5-hydroxymethylcytosine and increases levels of 5-methylcytosine

Journal Articles

Abstract 3987: Brain penetrant HDAC and PI3K/mTOR inhibitors synergize to induce DIPG cell death

Katherine Barnett, Hyuk Jean Kwon, Orlandi Novak, Charles Eberhart, Eric Raabe

Cancer Res (2022) 82 (12_Supplement): 3987.

https://doi.org/10.1158/1538-7445.AM2022-3987

Published: 15 June 2022

View article titled, Abstract 3987: Brain penetrant HDAC and PI3K/mTOR inhibitors synergize to induce DIPG cell death

Journal Articles

Abstract 5227: Combination therapy activating the integrated stress response synergistically suppresses proliferation and induces apoptosis in diffuse intrinsic pontine glioma

Orlandi V. Novak, Antje Arnold, Charles Eberhart, Eric H. Raabe

Cancer Res (2022) 82 (12_Supplement): 5227.

https://doi.org/10.1158/1538-7445.AM2022-5227

Published: 15 June 2022

View article titled, Abstract 5227: Combination therapy activating the integrated stress response synergistically suppresses proliferation and induces apoptosis in diffuse intrinsic pontine glioma

Journal Articles

Abstract 5226: The PI3K inhibitor Paxalisib combines synergistically with the pan-Raf inhibitor TAK580 (DAY 101) to extend survival in orthotopic xenograft models of atypical teratoid/rhabdoid tumors

Kristen Malebranche, Tyler Findlay, Charles Eberhart, Eric Raabe, Jeffrey Rubens

Cancer Res (2022) 82 (12_Supplement): 5226.

https://doi.org/10.1158/1538-7445.AM2022-5226

Published: 15 June 2022

View article titled, Abstract 5226: The PI3K inhibitor Paxalisib combines synergistically with the pan-Raf inhibitor TAK580 (DAY 101) to extend survival in orthotopic xenograft models of atypical teratoid/rhabdoid tumors

Journal Articles

Abstract 5225: The PI3K inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumors

Tyler Findlay, Kristen Malebranche, Charles Eberhart, Eric Raabe, Jeffrey Rubens

Cancer Res (2022) 82 (12_Supplement): 5225.

https://doi.org/10.1158/1538-7445.AM2022-5225

Published: 15 June 2022

View article titled, Abstract 5225: The PI3K inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumors

Journal Articles

Abstract 49: Brain penetrant HDAC inhibitor RG2833 induces DIPG cell death and synergizes with lomustine

Katherine K. Barnett, Orlandi Novak, Charles Eberhart, Eric Raabe

Cancer Res (2021) 81 (13_Supplement): 49.

https://doi.org/10.1158/1538-7445.AM2021-49

Published: 01 July 2021

View article titled, Abstract 49: Brain penetrant HDAC inhibitor RG2833 induces DIPG cell death and synergizes with lomustine

Journal Articles

Abstract 6226: Sapanisertib interferes with the NRF2-mediated stress response to synergize with Obatoclax and extend AT/RT survival

Ashlyn Parkhurst, Sabrina Wang, Harpreet Kaur, Antje Arnold, Charles Eberhart, Eric Raabe, Jeffrey Rubens

Cancer Res (2020) 80 (16_Supplement): 6226.

https://doi.org/10.1158/1538-7445.AM2020-6226

Published: 15 August 2020

View article titled, Abstract 6226: Sapanisertib interferes with the NRF2-mediated stress response to synergize with Obatoclax and extend AT/RT survival

Journal Articles

Abstract 3904: The novel combination of PAC-1 and ONC201 circumvent H3K27M-driven pro-survival gene expression to induce DIPG cell death

Ashlyn Parkhurst, Youngran Park, Antje Arnold, Michael Koldobskiy, Charles Eberhart, Eric Raabe, Jeffery Rubens

Cancer Res (2020) 80 (16_Supplement): 3904.

https://doi.org/10.1158/1538-7445.AM2020-3904

Published: 15 August 2020

View article titled, Abstract 3904: The novel combination of PAC-1 and ONC201 circumvent H3K27M-driven pro-survival gene expression to induce DIPG cell death

Journal Articles

Abstract 5267: Unbiased metabolic profiling of atypical teratoid/rhabdoid tumors predicts sensitivity to the glutamine metabolic inhibitor 6-diazo-5-oxo-L-norleucine

Sabrina Z. Wang, Brad Poore, Jesse Alt, Antoinette Price, Sariah Allen, Brent Orr, Rana Rais, Barbara Slusher, Charles Eberhart, Eric H. Raabe, Jeffrey H. Rubens

Cancer Res (2019) 79 (13_Supplement): 5267.

https://doi.org/10.1158/1538-7445.AM2019-5267

Published: 01 July 2019

View article titled, Abstract 5267: Unbiased metabolic profiling of atypical teratoid/rhabdoid tumors predicts sensitivity to the glutamine metabolic inhibitor 6-diazo-5-oxo-L-norleucine

Journal Articles

Abstract 3108: Inhibition of the mTOR and MAPK pathways suppresses growth, induces apoptosis, and decreases vascularity in pediatric low grade glioma

Antje Arnold, Lauren Harris, Ming Yuan, Fausto Rodriguez, Charles Eberhart, Eric Raabe

Cancer Res (2019) 79 (13_Supplement): 3108.

https://doi.org/10.1158/1538-7445.AM2019-3108

Published: 01 July 2019

View article titled, Abstract 3108: Inhibition of the mTOR and MAPK pathways suppresses growth, induces apoptosis, and decreases vascularity in pediatric low grade glioma

Journal Articles

Abstract 3120: The novel MEK inhibitor binimetinib decreases cell growth and induces apoptosis in AT/RT

Shubin Shahab, Jeffrey Rubens, Charles Eberhart, Eric Raabe

Cancer Res (2019) 79 (13_Supplement): 3120.

https://doi.org/10.1158/1538-7445.AM2019-3120

Published: 01 July 2019

View article titled, Abstract 3120: The novel MEK inhibitor binimetinib decreases cell growth and induces apoptosis in AT/RT

NARROW

Abstract 7555: Selective inhibition of the CoREST complex as a novel therapeutic target of atypical teratoid rhabdoid tumors

Abstract 5109: Novel acylfulvene LP184 shows single agent and combinatorial efficacy with PARP inhibitors in atypical teratoid rhabdoid tumors

Abstract 6565: Improving survival of atypical teratoid/rhabdoid tumor orthotopic xenografts through the combination of PI3K inhibitor paxalisib and nucleoside analog gemcitabine

Abstract 6498: MEK inhibitor mirdametinib suppresses MAP kinase pathway activity and inhibits tumor growth in atypical teratoid/rhabdoid tumors

Abstract 1141: The CoREST complex as a novel target to disrupt AT/RT’s abnormal epigenetic landscape

Abstract 5509: The PI3K inhibitor Paxalisib combines synergistically with the MEK inhibitor Mirdametinib to target atypical teratoid/rhabdoid tumors

Abstract 5490: Combination of the PI3k inhibitor Paxalisib with the nucleoside analog Gemcitabine over-activates the integrated stress response and induces atypical teratoid/rhabdoid tumor cell death

Abstract 6720: Using proteasome inhibition to hyperactivate the integrated stress response in aggressive pediatric brain tumors

Abstract 4990: Dual inhibitor of ACVR1 and MEK 1/2 E6201 and PI3K/mTOR inhibitor paxalisib synergistically inhibit cell growth in DMG

Abstract 5472: Inhibiting the TET pathway in diffuse midline glioma reduces levels of 5-hydroxymethylcytosine and increases levels of 5-methylcytosine

Abstract 3987: Brain penetrant HDAC and PI3K/mTOR inhibitors synergize to induce DIPG cell death

Abstract 5227: Combination therapy activating the integrated stress response synergistically suppresses proliferation and induces apoptosis in diffuse intrinsic pontine glioma

Abstract 5226: The PI3K inhibitor Paxalisib combines synergistically with the pan-Raf inhibitor TAK580 (DAY 101) to extend survival in orthotopic xenograft models of atypical teratoid/rhabdoid tumors

Abstract 5225: The PI3K inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumors

Abstract 49: Brain penetrant HDAC inhibitor RG2833 induces DIPG cell death and synergizes with lomustine

Abstract 6226: Sapanisertib interferes with the NRF2-mediated stress response to synergize with Obatoclax and extend AT/RT survival

Abstract 3904: The novel combination of PAC-1 and ONC201 circumvent H3K27M-driven pro-survival gene expression to induce DIPG cell death

Abstract 5267: Unbiased metabolic profiling of atypical teratoid/rhabdoid tumors predicts sensitivity to the glutamine metabolic inhibitor 6-diazo-5-oxo-L-norleucine

Abstract 3108: Inhibition of the mTOR and MAPK pathways suppresses growth, induces apoptosis, and decreases vascularity in pediatric low grade glioma

Abstract 3120: The novel MEK inhibitor binimetinib decreases cell growth and induces apoptosis in AT/RT

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only